Physician profile
Austin E Bach
NPI 1659706588
$11,638.70
in general payments reported to CMS, 2019-2025
39 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 91% of Pediatric Ophthalmology and Strabismus Specialist providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $403 · 2021: $2,133 · 2022: $3,042 · 2023: $2,935 · 2024: $1,071 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,633 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,633.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,890.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,706.91 | 2021-2023 | Tepezza |
| Santen INC. | $2,003.17 | 2023 | Verkazia |
| Eyevance Pharmaceuticals LLC | $1,628.26 | 2019-2022 | |
| Amgen INC. | $707.40 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $626.94 | 2022-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $420.85 | 2021-2025 | Misight Contact Lens, Myday Contact Lens |
| Kala Pharmaceuticals, INC. | $393.18 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $314.29 | 2021-2025 | Acthar |
| Alcon Vision LLC | $281.33 | 2019-2025 | Unity, Tryptyr, Simbrinza |
| Dompe US, INC. | $235.81 | 2022-2025 | Oxervate |
| Allergan, INC. | $211.66 | 2020-2022 | |
| Biotissue Holdings INC. | $186.58 | 2021-2025 | |
| Abbvie INC. | $180.79 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $161.43 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $140.28 | 2024-2025 | Xdemvy |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Bach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.